Neurophage Pharmaceuticals
HomeAbout UsOur ScienceNewsCareersContact Us

NeuroPhage extends Series B to $21.4M

. . . . . . . . . . . . . . . . . . . . . . . . . . . . .

NeuroPhage Receives Michael J. Fox Foundation Funding

. . . . . . . . . . . . . . . . . . . . . . . . . . . . .

NeuroPhage Selected as Top 10 CNS Biotech Company

 

© Neurophage Pharmaceuticals 2012

To advance the treatment of chronic neurodegenerative diseases through a novel, multi-target approach to reducing pathologic deposits of misfolded proteins.